Apimeds Pharmaceuticals US, Inc.
APUS · XNYSCIK 1894525fmd_0MBV36M13SRZ5XXWYT9HC2FMG5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Jun 30, 2026, 11 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Realized investment gains (losses) | – | – | 2 |
| Research and development | 0 | – | 2 |
| Total operating expenses | – | 1 | 12 |
| Operating income | (1) | (1) | (12) |
| Interest expense | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 |
| Other non-operating income (expense) | (0) | (0) | 6 |
| Net income | (1) | (1) | (6) |